Eli Lilly is seeing strong growth from its weight loss drugs. Investors are nervous about tariffs on drugs and weak data from ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

The iPhone maker's shares [rallied for a second day]( ...

The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight loss drug disappointed, ...

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...

Eli Lilly (LLY) has recently launched SenderraCare+, a digital solution paired with its biologic treatment EBGLYSS, and announced positive outcomes from a Phase 3 trial for the weight management drug ...

Good morning. Today, we read about the implications of mRNA funding cuts on national security, see layoffs at gene-editing ...